1 of 20
SENATE . . . . . . . . . . . . . . No. 2879
Senate, July 17, 2024 -- Text of amendment (36) (offered by Senator Miranda) to the Ways and
Means amendment (Senate, No. 2871) to the Senate Bill relative to health care market review
The Commonwealth of Massachusetts
_______________
In the One Hundred and Ninety-Third General Court
(2023-2024)
_______________
1 by adding the following sections:-
2 "SECTION XX. (a) (1) Notwithstanding any general or special law to the contrary, there
3is hereby established a Statewide Steering Committee on Sickle Cell Disease within the
4department of public health.
5 (2) The Steering Committee under this section shall consist of:
6 (A) two representatives from the Massachusetts Sickle Cell Disease Association
7including the Executive Director or their designee;
8 (B) three medical professionals from major Sickle Cell Disease treatment centers in the
9commonwealth who shall be appointed by the commissioner;
10 (C) the Executive Director of the Massachusetts Association of Community Health
11Workers or their designee;
12 (D) the President of the Massachusetts Chapter of the National Association of Social
13Workers or their designee; 2 of 20
14 (E) two members who shall be appointed by the commissioner, one of whom shall be an
15expert on the biology of the disease, and one of whom shall be an expert on the psycho-social
16aspect of the disease;
17 (F) two representatives of the department of elementary and secondary education who
18shall be appointed by the commissioner, including one of whom is knowledgeable about the right
19to comparable education, supportive services and accommodations under section 504 of the
20Rehabilitation Act of 1973;
21 (G) one representative of the Black and Latino Caucus who shall be appointed by the
22commissioner;
23 (H) one representative of the Asian Caucus who shall be appointed by the commissioner;
24 (I) two sickle cell disease patients who shall be appointed by the Governor, one of which
25shall be over 25 years in age and the other shall be between 18 and 25 years in age;
26 (J) a parent of a minor child with sickle cell disease who shall be appointed by the
27Governor;
28 (K) a parent of a secondary or post-secondary school age youth with sickle cell disease
29who shall be appointed by the commissioner; and
30 (L) one representative who has a background in racial health disparities who shall be
31appointed by the Governor.
32 The representatives of nongovernmental organizations shall serve staggered 3–year
33terms. Vacancies of unexpired terms shall be filled within 60 days by the appropriate appointing
34authority. 3 of 20
35 (3) The Steering Committee under this section shall:
36 (A) establish institution and community partnerships, including hospitals, and institutions
37of higher education;
38 (B) establish a statewide network of stakeholders, including parents, home health care
39providers, school-based nurses, and the Massachusetts Sickle Cell Disease Association who are
40committed to care for individuals with sickle cell disease collaboratively in an inclusive setting;
41 (C) establish a statewide network of racially and culturally competent stakeholders who
42include general and special education administrators and teachers and paraprofessionals;
43 (D) oversee the development of educational materials for individuals with sickle cell
44disease, the public, and health care providers about the assistance available to such individuals in
45the commonwealth, including local school district responsibilities for care of such individuals;
46 (E) identify funding sources for implementing or supporting the actions, studies, policies
47required by federal and state laws and regulations, or recommended by the Steering Committee,
48including funding from:
49 (i) state, federal, and local government sources; and
50 (ii) private sources;
51 (F) investigate and report on a standard of basic, multidisciplinary care for patients across
52the commonwealth; and
53 (G) establish subcommittees as appropriate. 4 of 20
54 (4) The department may, in consultation with the Statewide Steering Committee, provide
55services relating to sickle cell disease, including:
56 (A) educational programs on sickle cell disease for individuals affected by the disease,
57including:
58 (i) education on the rights of individuals with sickle cell disease, such as, without
59limitation, the right not to be discriminated against and the right to receive appropriate
60educational programming, health related services and accommodations necessary to access such
61programming and services;
62 (ii) expectations, options, and responsibilities of families of individuals with sickle cell
63disease;
64 (iii) challenges and responsibilities of caregivers of individuals with sickle cell disease;
65 (iv) obligations of employees at primary and secondary schools; and
66 (v) challenges and responsibilities of health care providers;
67 (B) social services support to individuals with sickle cell disease, including support from
68social workers and community health workers to provide information on services that may be
69available to the individual;
70 (C) hemoglobin electrophoresis or genetic testing for the presence of sickle cell disease;
71 (D) genetic counseling;
72 (E) assistance with any available reimbursement for medical expenses related to sickle
73cell disease; 5 of 20
74 (F) education and counseling services for parents and other family members and
75caretakers after the receipt of sickle cell trait test results from the Newborn Screening Program as
76required by section 270.006(A)(2)(e) of chapter 105, Code of Massachusetts Regulations,
77provided that, with the consent of parents and other family members and caretakers, such
78services may be provided in whole or in part by the Massachusetts Sickle Cell Disease
79Association; and
80 (G) any other programs or services that are necessary to decrease the use of acute care
81services by individuals who have sickle cell disease.
82 (5) The department shall, in consultation with any other agency of the commonwealth as
83the department determines appropriate, provide the services in paragraph (4) through
84community–based organizations, including specifically, pre-K, elementary and secondary
85schools as well as institutions for higher education for all affected school-age children, youth,
86and older students to the extent practicable.
87 (6) The Steering Committee, in conjunction with the department and other relevant
88stakeholders, shall study and make recommendations on:
89 (A) how to enhance access to services for individuals with sickle cell disease with a focus
90on areas in the commonwealth where there is a statistically high number of individuals with
91sickle cell disease or in areas where there is a lack of providers with expertise in treating sickle
92cell disease;
93 (B) whether to establish a sickle cell disease registry, and if recommended, the process
94and guidelines for establishing a registry and obtaining information consistent with informed
95consent and protecting data privacy; 6 of 20
96 (C) how to enhance the coordination of health care services for individuals with sickle
97cell disease who are transitioning from pediatric to adult health care, including the identification
98of available resources for individuals who are transitioning; and
99 (D) how to engage with community–based health fairs and other community–sponsored
100events in areas with a statistically high number of individuals with sickle cell disease to provide
101outreach and education on living with sickle cell disease and how to access health care services.
102 (b) The department shall, in consultation with the Steering Committee, establish and
103implement a system the provides information on the sickle cell trait to any individual who has
104the sickle cell trait and, if the individual is a minor, to the individual’s family.
105 (c) The department shall include the following in the information provided under
106subsection (b):
107 (1) how the sickle cell trait impacts the health of an individual with the trait;
108 (2) how the sickle cell trait is passed from a parent to a child; and
109 (3) implications for pregnancy.
110 (d) The department shall maintain in a conspicuous location on its website a list of
111resources for health care practitioners to use to improve their understanding and clinical
112treatment of individuals with sickle cell disease or the sickle cell trait, including information on
113the health impacts of carrying the sickle cell trait.
114 (e) For the purposes of this section, the following word shall, unless the context clearly
115requires otherwise, have the following meaning:- 7 of 20
116 “Steering Committee”, the Statewide Steering Committee on Sickle Cell Disease.
117 SECTION XX. (a) Notwithstanding any general or special law to the contrary, there is
118hereby established within the department of public health the sickle cell disease detection and
119education program to: (1) promote screening and detection of sickle cell disease, especially
120among unserved or underserved populations; (2) educate the public regarding sickle cell disease
121and the benefits of early detection; and (3) provide counseling and referral services.
122 (b) The program under this section shall include:
123 (1) establishment of a statewide public education and outreach campaign to publicize
124evidence-based sickle cell disease screening, detection and education services. The campaign
125shall include: general community education, outreach to specific underserved populations,
126evidence based clinical sickle cell disease screening services, and an informational summary that
127shall include an explanation of the importance of clinical examinations and what to expect during
128clinical examinations and sickle cell disease screening services;
129 (2) provision of grants to approved organizations pursuant to subsection (c) and for
130community based organizations pursuant to subsection (d);
131 (3) compilation of data concerning the program and dissemination of such data to the
132public; and
133 (4) development of health care professional education programs including the benefits of
134early detection of sickle cell disease and clinical examinations, the recommended frequency of
135clinical examinations and sickle cell disease screening services, and professionally recognized
136best practices guidelines. 8 of 20
137 (c)(1) Under the program, the commissioner of public health shall make grants in
138amounts appropriated to approved organizations for the provision of services relating to the
139evidence-based screening and detection of sickle cell disease as part of this program. The
140services required to be provided under such grants shall include:
141 (A) promotion and provision of early detection of sickle cell disease, including clinical
142examinations and sickle cell disease screening services;
143 (B) provision of counseling and information on treatment options and referral for
144appropriate medical treatment;
145 (C) dissemination of information to unserved and underserved populations as determined
146by the commissioner, to the general public and to health care professionals concerning sickle cell
147disease, the benefits of early detection and treatment, and the availability of sickle cell disease
148screening services at no cost to such populations;
149 (D) identification of local sickle cell disease screening services within the approved
150organization's region;
151 (E) provision of information, counseling and referral services to individuals diagnosed
152with sickle cell disease; and
153 (F) provision of information regarding the availability of medical assistance, including
154medical assistance for an individual who is eligible for such assistance pursuant to section 9 of
155chapter 118E of the General Laws, to an individual who requires treatment for sickle cell
156disease. 9 of 20
157 (2) The commissioner shall give notice and provide opportunity to submit applications
158for grants under the program. In order to be considered for a grant, an applicant must show
159evidence of the following, relating to the services the applicant proposes to provide:
160 (A) ability to provide and to ensure consistent and quality services under the program;
161 (B) expertise in providing the service;
162 (C) capacity to coordinate services with physicians, hospitals and other appropriate local
163institutions or agencies;
164 (D) ability to provide the service to unserved or underserved populations; and
165 (E) ability to provide the service in accordance with the standards specified in
166subdivision three of this section.
167 Applications shall be made on forms provided by the commissioner.
168 (3) The commissioner shall develop standards for the implementation of grants under the
169program by approved organizations, which shall ensure the following:
170 (A) integration of the approved organization with existing health care providers;
171 (B) maximizing third party reimbursement; and
172 (C) provision of services to unserved or underserved populations.
173 (4) Within the amounts of state or federal funds appropriated for the program, approved
174organizations may be authorized by the department to provide such services for populations 10 of 20
175served under this title. Services may include evidence based screening, patient education,
176counseling, follow-up and referral.
177 (5) Every organization receiving grants under this subsection shall submit to the
178commissioner, on or before October first of each year, a report of such organization's activities,
179including an assessment of the organization's programs and such data as the commissioner deems
180relevant and necessary to accomplish the purposes of the program
181 (d)(1) Under the program, the commissioner shall make grants within amounts
182appropriated for community based organizations to provide post-diagnosis counseling, education
183and outreach programs for persons diagnosed with sickle cell disease based upon criteria to be
184developed by the commissioner.
185 (2) The commissioner shall provide notice and opportunity for community-based
186organizations to submit applications to provide post-diagnosis sickle cell disease counseling,
187education and outreach programs. Such applications shall be on forms established by the
188commissioner.
189 (e) The commissioner shall submit, on or before December first of each year, an annual
190report to the governor and the legislature concerning the operation of the program. The reports
191shall include the experience of the program in providing services under this act. The annual
192report shall include strategies for implementation of the sickle cell disease awareness program
193and for promoting the awareness program to the general public, state and local elected officials,
194and various public and private organizations, associations, businesses, industries, and agencies.
195Organizations receiving grants under this act shall provide data and assessments as the 11 of 20
196commissioner may require for the report. The report shall include any recommendations for
197additional action to respond to the incidence of sickle cell disease in the commonwealth.
198 (f) For the purposes of this section, the following words shall, unless the context clearly
199requires otherwise, have the following meanings:-
200 “Community-based organizations”, free-standing organizations in which sickle cell
201disease survivors hold significant decision-making responsibility, and which offer a broad range
202of sickle cell disease education and support services free of charge.
203 “Program”, sickle cell disease detection and education program.
204 “Unserved or underserved populations", people having inadequate access and financial
205resources to obtain sickle cell disease screening and detection services, including people who
206lack health coverage or whose health coverage is inadequate or who cannot meet the financial
207requirements of their coverage for accessing detection services.
208 SECTION XX. (a)(1) Notwithstanding any general or special law to the contrary, the
209commissioner of public health or designee shall, in accordance with regulations adopted by the
210department of public health pursuant to subsection (b), and in consultation with the
211Massachusetts Sickle Cell Disease Association, establish and maintain a system for the reporting
212of information on sickle cell disease and its variants. Said system shall include a record of the
213cases of sickle cell disease and its variants which occur in the commonwealth along with such
214information concerning the cases as may be appropriate to form the basis for: (A) conducting
215comprehensive epidemiologic surveys of sickle cell disease and its variants in the
216commonwealth; and (B) evaluating the appropriateness of measures for the treatment of sickle
217cell disease and its variants. 12 of 20
218 (2) Hospitals, medical laboratories, and other facilities that provide screening, diagnostic
219or therapeutic services to patients with respect to sickle cell disease and its variants shall report
220the information prescribed by the regulation promulgated pursuant to subsection (b).
221 (3) Any provider of health care who diagnoses or provides treatment for sickle cell
222disease and its variants, except for cases directly referred to the provider or cases that have been
223previously admitted to a hospital, medical laboratory or other facility described in paragraph (2),
224shall report the information prescribed by the regulation adopted pursuant to subsection (b).
225 (b) The department of public health shall, by regulation:
226 (1) prescribe the form and manner in which information on cases of sickle cell disease
227and its variants must be reported in compliance with any applicable federal privacy law;
228 (2) prescribe the information that must be included in each report, which must include,
229without limitation: (A) the name, address, age and ethnicity of the patient; (B) the variant of
230sickle cell disease with which the person has been diagnosed; (C) the method of treatment; (D)
231any other diseases from which the patient suffers; (E) information concerning the usage of and
232access to health care services by the patient; and (F) if a patient diagnosed with sickle cell
233disease and its variants dies, his or her age at death and cause of death; and
234 (3) establish a protocol for allowing appropriate access to and preserving the
235confidentiality of the records of patients needed for research into sickle cell disease and its
236variants;
237 (4) establish a protocol for allowing information, in accordance with the preceding
238subsections, to be communicated with Statewide Steering Committee on Sickle Cell Disease, the 13 of 20
239sickle cell disease services program, and within the department as determined appropriate by the
240commissioner.
241 (c) The chief administrative officer of each health care facility in the commonwealth shall
242make available to the commissioner or designee the records of the health care facility for each
243case of sickle cell disease and its variants. The department of public health shall abstract from
244the records of a health care facility or shall require a health care facility to abstract from its own
245records such information as is required by regulations promulgated pursuant to subsection (b).
246The department shall compile the information in a timely manner and not later than 6 months
247after receipt of the abstracted information from the health care facility. The department shall by
248regulation adopt a schedule of fees which must be assessed to a health care facility for each case
249from which information is abstracted by the department. Any person who violates this section is
250subject to an administrative penalty established by regulation by the department.
251 (d) The department shall publish reports based upon the information obtained pursuant to
252subsections (a), (b), and (c) and shall make other appropriate uses of the information to report
253and assess trends in the usage of and access to health care services by patients with sickle cell
254disease and its variants in a particular area or population, advance research and education
255concerning sickle cell disease and its variants and improve treatment of sickle cell disease and its
256variants and associated disorders. The reports must include, without limitation:
257 (1) information concerning the locations in which patients diagnosed with sickle cell
258disease and its variants reside, the demographics of such patients and the utilization of health
259care services by such patients; 14 of 20
260 (2) the information described in paragraph (1), specific to patients diagnosed with sickle
261cell disease and its variants who are over 60 years of age or less than 5 years of age; and
262 (3) information on the transition of patients diagnosed with sickle cell disease and its
263variants from pediatric to adult care upon reaching 18 years of age.
264 (e) The department shall provide any qualified researcher whom the department
265determines is conducting valid scientific research with data from the reported information upon
266the researcher’s: (1) compliance with appropriate conditions as established under the regulations
267of the department; and (2) payment of a fee established by the department by regulation to cover
268the cost of providing the data.
269 (f) The commissioner or designee shall analyze the information obtained pursuant to
270subsections (a), (b) and (c) and the reports published pursuant to subsection (d) to determine
271whether any trends exist in the usage of and access to health care services by patients with sickle
272cell disease and its variants in a particular area or population.
273 (g) If the commissioner or designee determines that a trend exists in the usage of and
274access to health care services by patients with sickle cell disease and its variants in a particular
275area or population, the commissioner or designee shall work with appropriate governmental,
276educational and research entities to investigate the trend, advance research in the trend and
277facilitate the treatment of sickle cell disease and its variants and associated disorders.
278 (h) The department shall not reveal the identity of any patient, physician, or health care
279facility which is involved in any reporting required by this section unless the patient, physician
280or health care facility gives prior written consent to such a disclosure. A person or governmental
281entity that provides information to the department pursuant to this section shall not be held liable 15 of 20
282in a civil or criminal action for sharing confidential information unless the person or organization
283has done so in bad faith or with malicious purpose.
284 (i) For the purposes of this section, the following words shall, unless the context clearly
285requires otherwise, have the following meanings:-
286 “Sickle cell disease and its variants”, an inherited disease caused by a mutation in a gene
287for hemoglobin in which red blood cells have an abnormal crescent shape that causes them to
288block small blood cells and die sooner than normal.
289 SECTION XX. (a)(1) Notwithstanding any general or special law to the contrary, if a
290newborn screening for hereditary disorders performed pursuant to section 270.006(A)(2)(e) of
291chapter 105, Code of Massachusetts Regulations detects the presence of sickle cell trait, the
292laboratory performing the screening shall notify the physician responsible for the newborn’s care
293and shall document the patient’s information in the central registry established pursuant to
294paragraph (2) in a manner and on forms prescribed by the department of public health.
295 (2) The physician responsible for such newborn’s care shall provide the patient’s parents
296with information concerning the availability, benefits, and role of genetic counseling performed
297by a genetic counselor licensed pursuant to section 253 of chapter 112 of the General Laws,
298including a document available in multiple languages (as determined by the department) that
299identifies at least 10 genetic counselors and the public health care payers and private health care
300payers which contract with each such genetic counselor. In the case a physician described in the
301preceding sentence is not identified, the laboratory described in paragraph (1) shall provide the
302patient’s parents with such information relating to genetic counseling. Genetic counseling
303concerning a diagnosis of sickle cell trait shall include, but not be limited to, information 16 of 20
304concerning the fact that one or both of the parents carries sickle cell trait and the risk that other
305children born to the parents may carry sickle cell trait or may be born with sickle cell disease.
306 (b)(1) The commissioner of public health shall establish a central registry of patients
307diagnosed with sickle cell trait. The information in the central registry shall be used for the
308purposes of compiling statistical information and assisting the provision of follow-up counseling,
309intervention, and educational services to patients and to the parents of patients who are listed in
310the registry including, but not limited to, information concerning the availability and benefits of
311genetic counseling performed by a genetic counselor licensed pursuant to section 253 of chapter
312112 of the General Laws.
313 (2) The commissioner shall establish a system to notify the parents of patients who are
314listed in the registry that follow-up consultations with a physician are recommended for children
315diagnosed with sickle cell trait. Such notifications shall be provided: at least once when the
316patient is in early adolescence, when the patient may begin to participate in strenuous athletic
317activities that could result in adverse symptoms for a person with sickle cell trait; at least once
318during later adolescence, when the patient should be made aware of the reproductive
319implications of sickle cell trait; and at such other intervals as the commissioner may require.
320 (3) The commissioner shall establish a system under which the department shall make
321reasonable efforts to notify patients listed in the registry who reach the age of 18 years of the
322patient’s inclusion in the registry and of the availability of educational services, genetic
323counseling, and other resources that may be beneficial to the patient.
324 (4) Information on newborn infants and their families compiled pursuant to this section
325may be used by the department and agencies designated by the commissioner of public health for 17 of 20
326the purposes of carrying out this act, but otherwise the information shall not be a public record
327and shall be confidential and not divulged or made public so as to disclose the identity of any
328person to whom it relates, except as exempted or consented in accordance with section 10 of
329chapter 66 or section 70G of chapter 111 of the General Laws, respectively.
330 SECTION XX. (a) Notwithstanding any general or special law to the contrary, the
331division of medical assistance shall ensure the availability of accessible, quality health care for
332individuals with sickle cell disease who are enrolled in Medicaid managed care organizations or
333accountable care organizations that have a contract with the division to provide services to
334individuals enrolled under MassHealth pursuant to section 9 of chapter 118E of the General
335Laws. Such health care shall include, but not be limited to the following:
336 (1) comprehensive integrated care management for sickle cell disease, including primary
337care, specialized care, and mental health services;
338 (2) sickle cell trait testing and genetic counseling;
339 (3) social work services as well as education on disease management to patients,
340caregivers, and providers; and
341 (4) support navigating health insurance coverage and support with transportation to
342treatment centers.
343 (b) Not later than the fiscal year 2024 contract year, the division of medical assistance
344shall require Medicaid managed care or accountable care organizations to implement a sickle cell
345disease quality strategy for children and adults with sickle cell disease that includes, but is not
346limited to, the following components: 18 of 20
347 (1) measurable goals to improve the identification of members with sickle cell disease
348within 90 days after enrolling in the contracted health plan;
349 (2) to the extent practicable, adequate provider network capacity to ensure timely access
350to sickle cell disease specialty service providers, including, but not limited to, hematologists;
351 (3) care coordination strategies and supports to help members with sickle cell disease
352access sickle cell disease specialists and other related care supports;
353 (4) delivery of a training curriculum approved by the division of medical assistance to
354educate primary care providers on sickle cell disease, including information on emergency
355warning signs and complications, evidence-based practices and treatment guidelines, and when
356to make referrals to specialty sickle cell disease treatment providers; and
357 (5) in the case of an individual who is diagnosed with sick cell disease, exceptions to
358otherwise applicable prior authorization or dispensing limits for pain medications that are
359designed to reduce barriers for such an individual to be able to obtain the appropriate dosage and
360amount of a pain medication in a timely manner.
361 (c) The division of medical assistance shall also do the following:
362 (1) Not later than the fiscal year 2025 contract year, require each Medicaid managed care
363organization and accountable care organization to report, on a quarterly basis, an unduplicated
364count of children and adults identified as having sickle cell disease enrolled with the contracted
365plan during the quarter. The department shall publish these reports, by contracted plan, on the
366department's website. 19 of 20
367 (2) Not later than January 1, 2025, and in partnership with Medicaid managed care
368organizations and accountable care organizations, identify, document, and share best practices
369regarding sickle cell disease care management and care coordination with Medicaid-enrolled
370primary care and sickle cell disease specialty providers with a goal of improving services for
371members with sickle cell disease and their families.
372 (3) Enter into a contract not later than January 1, 2025, with a publicly funded university
373to develop a sickle cell disease-focused comprehensive assessment tool or a supplement to an
374existing comprehensive assessment tool to screen members identified with sickle cell disease for
375comorbidities, medical history for the treatment of sickle cell disease including disease-
376modifying medications and pain management, psychosocial history, barriers to accessing or
377completing treatments, social supports, other care coordinators working with the member,
378community resources being used or needed, quality of life, and personal preferences for
379engagement with a care coordinator.
380 (4) Not later than the fiscal year 2025 contract year, establish performance measures
381relative to access to care and available therapies, engagement in treatment, and outcomes for
382individuals with sickle cell disease, with the metrics to be reported annually by the
383comprehensive health care program to Medicaid managed care organizations and accountable
384care organizations and with incentive payments attached to the measures.
385 (5) Not later than January 1, 2025, develop a plan for improving the transition from
386pediatric care to adult care for adolescents with sickle cell disease who are aging out of the
387Medicaid program, and a plan for helping qualified beneficiaries maintain Medicaid coverage
388under another eligibility category, in order to maintain continuity of care. 20 of 20
389 (d) The division of medical assistance shall provide an annual sickle cell disease
390management and accountability report to the senate and house committees on ways and means,
391including the status of sickle cell disease-focused access to care, quality of services, health
392outcomes, and disparities in the commonwealth.
393 (e) The division of medical assistance shall incorporate the sickle cell disease
394management and accountability standards into its contracts with managed care plans and
395accountable care organizations, including financial or administrative penalties for lack of
396performance. Contracted plan rates must be adjusted to reflect enhanced care or other provisions
397that are shifted to the contracted plans."